Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Eligibility Criteria

• * Male or female and 5 through 30 years of age
• * Prader-Willi syndrome with a documented disease-causing mutation
• * Increased appetite with decreased satiety accompanied by food seeking (consistent with PWS Nutritional Phase 3)
• * HQ-CT total score of ≥13 at Screening and Baseline
• * CGI-S score for hyperphagia in PWS of ≥4 at Screening and Baseline
• * Lives with a caregiver who understands and is willing and able to adhere to study-related procedures and is willing to participate in all study visits
• * Genetically diagnosed with Schaaf-Yang syndrome or another genetic, hormonal, or chromosomal cognitive impairment besides PWS
• * An active upper respiratory infection at the Screening visit or the Baseline visit
• * Any clinically significant cardiovascular disorder, renal, hepatic, gastrointestinal, or respiratory disease, including severe asthma
• * History of, or current, cerebrovascular disease, brain trauma, epilepsy, or frequent migraines. A history of febrile seizures is not exclusionary
• * Nasal surgery within 1 month of Screening visit or planning to have nasal surgery during the study.
• * Unwilling to abstain from nasal saline, other nasal irrigation, and other intranasal medications during the Screening period and through the treatment period of the study
• * Clinically significant irritability or agitation, requiring initiation of or increase in the dose of antipsychotic medication, within the 6 months prior to the Screening visit
• * Used prostaglandins, prostaglandin analogues, or prostaglandin agonists in the 3 months prior to the Baseline visit. Inhibitors of prostaglandin synthesis, such as nonsteroidal anti-inflammatory drugs, are not exclusionary.
• * Started a glucagon-like peptide 1 (GLP-1) agonist within the 6 months prior to the Screening visit. Treatment with GLP-1 agonist is allowed if the subject has been taking it for more than 6 months prior to Screening.
• * Used oxytocin, desmopressin (DDAVP), or tesofensine within 6 months prior to the Baseline visit
• * Active psychotic symptoms, a history of psychotic symptoms, or a psychotic disorder
• * History of suicide attempt or inpatient psychiatric hospitalization
• * New food-related interventions, including environment or dietary restrictions, within 1 month of the Screening visit